Hynic-toc
Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging. Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
For research use only. We do not sell to patients.
- CAS No.: 257943-19-4
- Formula: C55H71N13O12S2
- Molecular Weight:1170.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 257943-19-4
-
Molecular Weight 1170.36
-
Formula C55H71N13O12S2
-
Synonyms
HYNIC-Tyr3-octreotide
-
Sequence
{Hynic}-{d-Phe}-Cys-Tyr-{d-Trp}-Lys-Thr-Cys-{Thr-ol} (Disulfidebridge:Cys2-Cys7)
-
Sequence Shortening
{Hynic}-{d-Phe}-CY-{d-Trp}-KTC-{Thr-ol} (Disulfidebridge:Cys2-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Bioluminescent/Fluorescent Imaging Xenograft
Bioluminescent and fluorescent imaging xenograft models use tumor cells engineered to express optical reporters so tumor engraftment, growth, dissemination, and treatment response can be monitored longitudinally in living animals and validated ex vivo. Bioluminescence imaging usually measures luciferase activity after substrate administration and is commonly used as a surrogate for viable reporter-expressing tumor burden, while fluorescence imaging measures reporter or probe emission and can support tumor localization, ex vivo confirmation, or complementary multimodal analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)